**7. Conclusions**

In conclusion, Acinetobacter strains are important pathogens due to the diversity of their reservoirs, capacity to accumulate mechanisms of antimicrobial resistance and outbreak potential. Acinetobacter infections prolong the length of hospital stay, increase mortality and have economic impact. The greatest challenge remain prevention, control and treatment of infections caused by multidrug-resistant strains of Acinetobacter.

Although our understanding of Acinetobacter made an significant step forward, there are still many unanswered questions for health care workers. Future directions should be directed toward research development of new antibiotics, well-controlled clinical trials of antimicrobial regimens and combinations, and prevention of health care-associated transmission of multi‐ drug-resistant Acinetobacter infections.

[7] Davis, K. A, Moran, K. A, Mcallister, C. K, & Gray, P. G. Multidrug-resistant Acineto‐ bacter extremity infections in soldiers. Emerg Infect Dis. (2005). , 11, 1218-1224.

Acinetobacter

91

http://dx.doi.org/10.5772/55618

[8] Doughari, H, Ndakiedemi, P, Human, I, & Benade, S. The Ecology, Biology and Pathogenesis of Acinetobacter spp.: An Overview. Microbes Environ. (2011). , 26(2),

[9] Ecker, J. A, Massire, C, Hall, T. A, et al. Identification of Acinetobacter species and genotyping of Acinetobacter baumannii by multilocus PCR and mass spectrometry. J

[10] Evans, B. A, Hamouda, A, & Amyes, S. G. The Rise of Carbapenem-Resistant Acine‐

[11] Falagas, M. E, Karveli, E. A, Kelesidis, I, & Kelesidis, T. Community-acquired Acine‐ tobacter infections. Eur J Clin Microbiol Infect Dis. (2007). , 26(12), 857-868.

[12] Fournier, P, Vallenet, D, & Barbe, V. et. al. Comparative Genomics of Multidrug Re‐

[13] Fournier, P. E, & Richet, H. The epidemiology and control of Acinetobacter bauman‐

[14] Giamarellou, H, & Poulakou, G. Pharmacokinetic and pharmacodynamic evaluation

[15] Guide to the Elimination of Multidrug-resistant Acinetobacter baumannii Transmis‐

[16] Imperi, F, Antunes, L. C, Blom, J, Villa, L, Iacono, M, Visca, P, & Carattoli, A. The genomics of Acinetobacter baumannii: insights into genome plasticity, antimicrobial

[17] Kempf, M, & Rolain, J. M. Emergence of resistance to carbapenems in Acinetobacter baumannii in Europe: clinical impact and therapeutic options. Int J Antimicrob

[18] Livermore, D. M. Fourteen years in resistance. Int J Antimicrob Agents. (2012). ,

[19] Maragakis, L. L, & Perl, T. M. Acinetobacter baumannii: epidemiology, antimicrobial resistance, and treatment options. Clin Infect Dis. (2008). Apr 15;, 46(8), 1254-1263. [20] Shea, O. MK. Acinetobacter in modern warfare. Int J Antimicrob Agents. (2012).

[21] Peleg, A. Y, Seifert, H, & Paterson, D. L. Acinetobacter baumannii: emergence of a

successful pathogen. Clin Microbiol Rev. (2008). Jul;, 21(3), 538-582.

sistance in Acinetobacter baumannii. PLoS Genet. (2006). , 2, 62-72.

nii in health care facilities. Clin Infect Dis. (2006). , 42(5), 692-699.

of tigecycline. Expert Opin Drug Metab Toxicol. (2011). , 7(11), 1459-70.

resistance and pathogenicity. IUBMB Life. (2011). Dec;, 63(12), 1068-74.

101-112.

Clin Microbiol. (2006). , 44(8), 2921-2932.

tobacter baumannii. Curr Pharm Des. (2012).

sion in Healthcare SettingsAPIC Guide (2010).

Agents. (2012). , 39(2), 105-14.

39(4), 283-94.

May;, 39(5), 363-75.
